Agoracom Blog Home

Archive for the ‘Plant-Based Food’ Category

PlantX $VEGA.ca joins 38.4 billion USD North American pet food industry by launching pet food vertical with #Kirtana Inc. products $BYND $TSN $CAG $FMCI $VERY $MEAT

Posted by AGORACOM-JC at 8:48 AM on Friday, October 9th, 2020
PlantX | LinkedIn
  • Announced that the Company’s ecommerce platform www.PlantX.com and www.PlantX.ca will begin featuring pet food products from Kirtana Inc.
  • The products PlantX will offer from Kirtana Inc. on its digital platform www.PlantX.com are all ethical and eco-friendly. The key ingredients used in the products include oats, maize, soy, pea protein, and sunflower seeds
  • “Launching the pet food section of PlantX.com with Kirtana Inc. products is very exciting,” said Sean Dollinger, PlantX founder. “Now we can offer a plant-based lifestyle to both human consumers and their pets.”

VANCOUVER, BC, Oct. 9, 2020  – PlantX Life Inc. (the “Company” or “PlantX“) (CSE: VEGA) (Frankfurt: WNT1) is pleased to announce that the Company’s ecommerce platform www.PlantX.com and www.PlantX.ca will begin featuring pet food products from Kirtana Inc.

PlantX adds plant-based pet food (CNW Group/PlantX Life Inc.)

The addition of plant-based pet foods allows PlantX, the digital face of the plant-based community and the one-stop-shop for everything plant-based, to further expand its category verticals. The Kirtana Inc. pet food offerings will be available to order in the new pet food section of the Company’s ecommerce platform PlantX.ca/vegan-pet-food.

PlantX is now able to offer a variety of pet food products from Kirtana Inc. including Evolution Diet, Ami and Benevo brands, featuring plant-based dry kibble formulas, an assortment of wet food in cans, and delicious vegan bone treats. Ami cat formula is well recognized among cat guardians, while Benevo offers a unique organic formula. Evolution Diet provides nutrition for dogs and cats of all life-stages with non-GMO and organic formulas.

The products PlantX will offer from Kirtana Inc. on its digital platform www.PlantX.com are all ethical and eco-friendly. The key ingredients used in the products include oats, maize, soy, pea protein, and sunflower seeds. The products have been formulated in accordance with AAFCO/FEDIAF nutritional standards to ensure that cats and dogs get 100% of the nutrients that they need to be healthy and thrive.

“Launching the pet food section of PlantX.com with Kirtana Inc. products is very exciting,” said Sean Dollinger, PlantX founder. “Now we can offer a plant-based lifestyle to both human consumers and their pets.”

“By adding pet food to the website, we have touched on a product that is meaningful around the world. We are very proud to be partnering with Kirtana Inc. It’s refreshing to know that the PlantX team goes through a lengthy process before partnering with brands. I am proud to invest in a company like PlantX that ensures all partners live up to these standards,” said Morris Hoffman, PlantX shareholder.

The Company website is http://investor.PlantX.com/.

About PlantX Life Inc.

As the digital face of the plant-based community, PlantX’s platform is the one-stop-shop for everything plant-based. With its fast growing category verticals, the Company offers customers across North America more than 10,000 plant-based products. In addition to offering meal and indoor plant deliveries, the Company currently has plans underway to expand its product lines to include cosmetics, clothing, and its own water brand — but the business is not limited to an e-commerce platform. The Company uses its digital platform to build a community of like-minded consumers, and most importantly, provide education. Its successful enterprise is being built and fortified on partnerships with top nutritionists, chefs, and brands. The Company eliminates the barriers to entry for anyone interested in living a plant-based lifestyle, and thriving in a longer, healthier, and happier life.

Forward-Looking Information

This press release contains “forward-looking information” within the meaning of applicable securities laws. All statements contained herein that are not clearly historical in nature may constitute forward-looking information. In some cases, forward-looking information can be identified by words or phrases such as “may”, “will”, “expect”, “likely”, “should”, “would”, “plan”, “anticipate”, “intend”, “potential”, “proposed”, “estimate”, “believe” or the negative of these terms, or other similar words, expressions and grammatical variations thereof, or statements that certain events or conditions “may” or “will” happen, or by discussions of strategy. The forward-looking information contained herein includes statements regarding the offering and availability of Kirtana Inc. products in the pet food section of the Company’s ecommerce platform, and the business and strategic plans of the Company.

By their nature, forward-looking information is subject to inherent risks and uncertainties that may be general or specific and which give rise to the possibility that expectations, forecasts, predictions, projections or conclusions will not prove to be accurate, that assumptions may not be correct and that objectives, strategic goals and priorities will not be achieved. A variety of factors, including known and unknown risks, many of which are beyond our control, could cause actual results to differ materially from the forward-looking information in this press release including, without limitation: the Company’s ability to comply with all applicable governmental regulations including all applicable food safety laws and regulations; impacts to the business and operations of the Company due to the COVID-19 epidemic; a limited operating history, the ability of the Company to access capital to meet future financing needs; the Company’s reliance on management and key personnel; competition; changes in consumer trends; foreign currency fluctuations; and general economic, market or business conditions.

Additional risk factors can also be found in the Company’s continuous disclosure documents which have been filed on SEDAR and can be accessed at www.sedar.com. Readers are cautioned to consider these and other factors, uncertainties and potential events carefully and not to put undue reliance on forward-looking information. The forward-looking information contained herein is made as of the date of this press release and is based on the beliefs, estimates, expectations and opinions of management on the date such forward-looking information is made. The Company undertakes no obligation to update or revise any forward-looking information, whether as a result of new information, estimates or opinions, future events or results or otherwise or to explain any material difference between subsequent actual events and such forward-looking information, except as required by applicable law.

SOURCE PlantX Life Inc.

Innocan Phrama $INNO.ca Completes Successful Cosmetic Clinical Studies Demonstrating the Efficacy of Its SHIR(TM) CBD Premium Facial Serum on Skin Hydration $GWPH $CRDL.ca $PCLO.ca

Posted by AGORACOM-JC at 4:07 PM on Tuesday, September 15th, 2020
Innocan-Blog
  • Completed a cosmetic clinical study examining the impact of its SHIR ™ Premium CBD Facial Serum containing 300 mg of cannabidiol on skin hydration
  • Results demonstrated that there were significant hydration increases for each period
  • The Serum was well tolerated with no uncomfortable symptoms or feelings reported by the subjects of the study

Herzliya, Israel and Calgary, Alberta–(September 15, 2020) –   Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (the “Company” or “Innocan“), is pleased to announce today, that it has completed a cosmetic clinical study examining the impact of its SHIR ™ Premium CBD Facial Serum containing 300 mg of cannabidiol (“CBD“) (the “Serum”) on skin hydration.

The study was conducted by an independent research laboratory: INOVAPOTEK, Pharmaceutical Research and Development in Portugal”. The study aimed to assess the hydrating efficacy of the Serum in vivo, by measuring the skin capacitance for a period of 2, 4, 8 and 24 hours after the CBD Serum application on the skin. The results demonstrated that there were significant hydration increases for each period. The Serum was well tolerated with no uncomfortable symptoms or feelings reported by the subjects of the study.

In addition, the research laboratory completed a clinical controlled study for the evaluation of the acute cutaneous irritation potential of cosmetic products. All of the SHIR™ Derma Cosmetic products tested to date have demonstrated to be non-irritating under the test conditions.

“The results of these studies have demonstrated the efficacy of the SHIR ™ Premium CBD Facial Serum product. Hydrating the skin is one of the most crucial measures to keep the skin healthy, young and also to eliminate wrinkles. The amazing results of the new clinical studies are in addition to Innocan’s research and development efforts to bring to market, a trustworthy product that will set a new industry standard, stated Iris Bincovich, Chief Executive Officer of Innocan.”

Figure 1

To view an enhanced version of Figure 1, please visit:
https://orders.newsfilecorp.com/files/6922/63880_98aa5e38b4389924_003full.jpg

About Innocan

The Company, through its wholly owned subsidiary, Innocan Israel, is a pharmaceutical tech company that focuses on the development of several drug delivery platforms containing CBD. Innocan Israel and Ramot at Tel Aviv University, are collaborating on a new, revolutionary exosome-based technology that targets both central nervous system (CNS) indications and the Covid-19 Corona Virus using CBD. CBD-loaded exosomes hold the potential to help in the recovery of infected lung cells. This product, which is expected to be administrated by inhalation, will be tested against a variety of lung infections.

Innocan Israel signed a worldwide exclusive license agreement with Yissum, the commercial arm of the Hebrew University of Jerusalem, to develop a CBD drug delivery platform based on a unique-controlled release liposome to be administrated by injection. Innocan Israel plans, together with Professor Berenholtz Head of the Laboratory of Membrane and Liposome Research of the Hebrew University, to test the liposome platform on several potential indications. Innocan Israel is also working on a dermal product that integrates CBD with other pharmaceutical ingredients as well as the development and sale of CBD-integrated pharmaceuticals, including, but not limited to, topical treatments for relief of psoriasis symptoms as well as the treatment of muscle pain and rheumatic pain. The founders and officers of Innocan Israel have commercially successful track records in the pharmaceutical and technology sectors in Israel and globally.

For further information, please contact:

For Innocan Pharma Corporation:
Iris Bincovich, CEO
+972-54-3012842
[email protected]

NEITHER THE CANADIAN SECURITIES EXCHANGE NOR ITS REGULATION SERVICES PROVIDER HAVE REVIEWED OR ACCEPT RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE.

Caution regarding forward-looking information

Certain information set forth in this news release, including, without limitation, information regarding the markets, requisite regulatory approvals and the anticipated timing for market entry, is forward-looking information within the meaning of applicable securities laws. By its nature, forward-looking information is subject to numerous risks and uncertainties, some of which are beyond Innocan’s control. The forward-looking information contained in this news release is based on certain key expectations and assumptions made by Innocan, including expectations and assumptions concerning the anticipated benefits of the products, satisfaction of regulatory requirements in various jurisdictions and satisfactory completion of requisite production and distribution arrangements.

Forward-looking information is subject to various risks and uncertainties which could cause actual results and experience to differ materially from the anticipated results or expectations expressed in this news release. The key risks and uncertainties include but are not limited to: general global and local (national) economic, market and business conditions; governmental and regulatory requirements and actions by governmental authorities; and relationships with suppliers, manufacturers, customers, business partners and competitors. There are also risks that are inherent in the nature of product distribution, including import / export matters and the failure to obtain any required regulatory and other approvals (or to do so in a timely manner) and availability in each market of product inputs and finished products. The anticipated timeline for entry to markets may change for a number of reasons, including the inability to secure necessary regulatory requirements, or the need for additional time to conclude and/or satisfy the manufacturing and distribution arrangements. As a result of the foregoing, readers should not place undue reliance on the forward-looking information contained in this news release concerning the timing of launch of product distribution. A comprehensive discussion of other risks that impact Innocan can also be found in Innocan’s public reports and filings which are available under Innocan’s profile at www.sedar.com.

Readers are cautioned that undue reliance should not be placed on forward-looking information as actual results may vary materially from the forward-looking information. Innocan does not undertake to update, correct or revise any forward looking information as a result of any new information, future events or otherwise, except as may be required by applicable law.